William Blair Brokers Increase Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at William Blair upped their Q3 2025 EPS estimates for Apellis Pharmaceuticals in a report released on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($0.15) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.73) EPS and Q1 2026 earnings at $0.02 EPS.

Several other analysts also recently weighed in on APLS. Scotiabank boosted their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. JPMorgan Chase & Co. upped their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Finally, Wedbush lowered their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.59.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $22.52 on Friday. The company has a 50-day moving average price of $26.42 and a two-hundred day moving average price of $29.16. The firm has a market capitalization of $2.83 billion, a PE ratio of -11.09 and a beta of 0.85. Apellis Pharmaceuticals has a twelve month low of $21.70 and a twelve month high of $58.12. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.73) EPS.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the transaction, the chief financial officer now owns 88,100 shares in the company, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,054 shares of company stock worth $1,952,719 over the last 90 days. 6.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of APLS. Avoro Capital Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 10.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock valued at $390,011,000 after purchasing an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. increased its stake in Apellis Pharmaceuticals by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company’s stock worth $320,569,000 after purchasing an additional 230,450 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after buying an additional 735,160 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after purchasing an additional 939,289 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Apellis Pharmaceuticals by 127.2% during the 4th quarter. AQR Capital Management LLC now owns 1,856,442 shares of the company’s stock worth $59,239,000 after acquiring an additional 1,039,182 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).